BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 30654067)

  • 1. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
    Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
    J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
    Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
    Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.
    Palmer A; Papaluca T; Stoové M; Winter R; Pedrana A; Hellard M; Wilson D; Thompson A; Scott N;
    Int J Drug Policy; 2021 Aug; 94():103203. PubMed ID: 33744667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
    Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
    Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
    Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
    Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
    Fiore V; Rastrelli E; Madeddu G; Ranieri R; De Vito A; Giuliani R; Di Mizio G; Bolcato M; De Matteis G; Ialungo AM; Dell'Isola S; Starnini G; Babudieri S
    BMC Infect Dis; 2022 Jul; 22(1):601. PubMed ID: 35799126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus recommendations on the management of hepatitis C in Australia's prisons.
    Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
    Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont.
    Hale AJ; Mathur S; Dejace J; Lidofsky SD
    Public Health Rep; 2023; 138(2):265-272. PubMed ID: 35264027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
    Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
    Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.
    Snow KJ; Young JT; Preen DB; Lennox NG; Kinner SA
    BMC Public Health; 2014 Aug; 14():830. PubMed ID: 25113132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study.
    Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P
    Liver Int; 2023 Mar; 43(3):569-579. PubMed ID: 36305315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
    Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
    BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.